Deglycosylated RBD produced in <i>Pichia pastoris</i> as a low-cost sera COVID-19 diagnosis tool and a vaccine candidate
Tommy Idrovo-Hidalgo, María F. Pignataro, Luis M. Bredeston, Fernanda Elias, María Georgina Herrera, María Florencia Pavan, Sabrina Foscaldi, Mayra Suireszcz, Natalia Fernández, Diana E. Wetzler, Carlos H. Paván, Patricio O. Craig, Ernesto A. Román, Lucas Ruberto, Diego G. Noseda, Lorena I. Ibañez, Cecilia Czibener, Mordecai P. Blaustein, Luis M. Bredeston, Patricio O. Craig, Cecilia D’Alessio, Fernanda Elias, Natalia Fernández, Gustavo E. Gudesblat, M. Guillermo Herrera, Lorena I. Ibañez, Tommy Idrovo-Hidalgo, Alejandro D. Nadra, Diego G. Noseda, Carlos Paván, María F. Pignataro, E. Román, Lucas Ruberto, Natalia Rubinstein, Javier Santos, Diana E. Wetzler, Alicia M. Zelada, Juan E. Ugalde, Alejandro D. Nadra, Javier Santos, Cecilia D’Alessio
Abstract
During the COVID-19 outbreak, numerous tools including protein-based vaccines have been developed. The methylotrophic yeast Pichia pastoris (synonymous to Komagataella phaffii) is an eukaryotic cost-effective and scalable system for recombinant protein production, with the advantages of an efficient secretion system and the protein folding assistance of the secretory pathway of eukaryotic cells. In a previous work, we compared the expression of SARS-CoV-2 Spike Receptor Binding Domain in P. pastoris with that in human cells. Although the size and glycosylation pattern was different between them, their protein structural and conformational features were indistinguishable. Nevertheless, since high mannose glycan extensions in proteins expressed by yeast may be the cause of a nonspecific immune recognition, we deglycosylated RBD in native conditions. This resulted in a highly pure, homogenous, properly folded and monomeric stable protein. This was confirmed by circular dichroism and tryptophan fluorescence spectra and by SEC-HPLC, which were similar to those of RBD proteins produced in yeast or human cells. Deglycosylated RBD was obtained at high yields in a single step, and it was efficient in distinguishing between SARS-CoV-2-negative and positive sera from patients. Moreover, when the deglycosylated variant was used as an immunogen, it elicited a humoral immune response ten times greater than the glycosylated form, producing antibodies with enhanced neutralizing power and eliciting a more robust cellular response. The proposed approach may be used to produce at a low cost, many antigens that require glycosylation to fold and express, but do not require glycans for recognition purposes.